Ocular melanogenesis: The role of antioxidants

Ophthalmic Research

Volumn 36, Issue 6, 2004, Pages 303-311

  Sarangarajan, Rangaprasad ^a   Apte, Shireesh P ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Baxter IV Systems   (United States)

Author keywords

Antioxidants; Melanin; Melanogenesis; Ocular degeneration; Redox

Indexed keywords

ACETYLCYSTEINE; AGENTS ACTING ON THE EYE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BUTYLATED HYDROXYANISOLE; CYSTEINE; GLUTATHIONE; HYDROQUINONE; NICOTINAMIDE; OXYRESVERATROL; POLCYCLITOL; PYRROLIDINE DITHIOCARBAMATE; QUERCETIN; RESVERATROL; SALACINOL; SCAVENGER; SODIUM METABISULFITE; STILBENE DERIVATIVE; THIOCTIC ACID; UBIQUINONE; UBISEMIQUINONE; UNCLASSIFIED DRUG; VISUAL PIGMENT;

DRUG ACTIVITY; DRUG POTENCY; EYE; HUMAN; MELANOGENESIS; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; EYE; HUMANS; MELANINS; MELANOCYTES;

EID: 11244313843     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081632     Document Type: Review

References (112)

1. Sarna T: Properties and function of the ocular melanin - a photobiological view. J Photochem Photobiol B 1992;12:215-258.
2. Wistrand PJ, et al: The incidence and timecourse of latanoprost induced iridal pigmentation as a function of eye color. Surv Ophthalmol 1997;41(suppl 2):129-138.
3. Stjernschantz J, et al: Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analog. Exp Eye Res 1999;68:431-436.
4. Levin LA, Dutkiewicz R, Albert DM: Effect of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res 2000;70:563-569.
5. Landrum JT, Bone RA, Kilburn MD: The macular pigment: A possible role in protection from age-related macular degeneration. Adv Pharmacol 1997;38:537-556.
6. Rapp LM, Williams TP: The role of ocular pigmentation in protecting against retinal light damage. Vis Res 1980;20:1127-1131.
7. Hearing VJ, et al: Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res 1989;2:75-85.
8. Nordland JJ, et al: The pigmentary system: An expanded perspective. Annal Dermatol 1994;6:109-124.
9. Sarna T, Swartz A: The physical properties of melanin; in Nordlund JJ, Boissy RE, Hearing JT, King RA, Ortonne JP (eds): The Pigmentary System: Physiology and Pathophysiology. Oxford, Oxford University Press, 1998, pp 333-358.
10. Sarangarajan R, Boissy RE: Tyrp1 and oculocutaneous albinism. Pigment Cell Res 2001;14:437-444.
11. Smith-Thomas L, Richardson P, Thody AJ, et al: Human ocular melanocytes and retinal pigment epithelial cells differ in their melanogenic properties in vivo and in vitro. Curr Eye Res 1996;15:1079-1091.
12. Boulton M: The role of melanin in the RPE; in Marmor M, Wolfensberger T (eds): The Retinal Pigment Epithelium. Oxford, Oxford University Press, 1998, pp 68-85.
13. Schraermeyer U: Does melanin turnover occur in the eyes of adult vertibrates? Pigment Cell Res 1993;6:193-204.
14. Boulton M, Docchio F, Dayhaw-Baker P, et al: Age related changes in the morphology, absorption and fluorescence of melanosomes and lipofuscin granules of the retinal pigment epithelium. Vision Res 1990;30:1291-1303.
15. Schraermeyer U, Peters S, Thumann G, et al: Melanin granules of retinal pigment epithilium are connected with the lysosomal degradation pathway. Exp Eye Res 1999;68:237-245.
16. Prota G, Hu DN, Vincensi MR, et al: Characterization of melanins in the human irides and cultures of uveal melanocytes from eyes of different colors. Exp Eye Res 1998;67:293-299.
17. Sarna T, et al: Free radical scavenging properties of melanin. Interaction of eu and pheo melanin models with reducing and oxidizing agents. Free Radic Biol Med 1999;26:518-525.
18. Simon JD, et al: Aggregation of eumelanin mitigates photogeneration of reactive oxygen species. Free Radic Biol Med 2002;32:720-730.
19. Hearing VJ, Virador VM, Kobayashi N, et al: A standardized protocol for assessing regulators of pigmentation. Anal Biochem 1999;270:207-219.
20. Martin A: Physical Pharmacy, ed 4. Philadelphia, Lea and Febiger, 1993, pp 190-212.
21. Hearing VJ, et al: Metal ligand binding specificities of the tyrosinase related proteins. Biochem Biophys Res Commun 1998;242:579-585.
22. Solano F, et al: Dopachrome tautomerase is a zinc-containing enzyme. Biochem Biophys Res Comm 1994;204:1243-1250.
23. Gopalakrishna R, Jaken S: Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000;28:1349-1361.
24. Chen Z, et al: Curcumin irreversibly inactivates protein kinase C and phorbol ester binding: Its possible role in cancer chemoprevention. Proc Am Assoc Cancer Res 1996;37:A1922.
25. Park HY, Wu H: Protein kinase C mediated complex formation between tyrosinase and TRP-1. Biochem Biophys Res Commun 2003;311:948-953.
26. Ward NE, Pierce DS, Chung SE, et al: Irreversible inactivation of protein kinase C by glutathione. J Biol Chem 1998;273:12558-12566.
27. Boscoboinik D, Szewczyk A, Hensey C, et al: Inhibition of cell proliferation by α-tocopherol. Role of protein kinase C. J Biol Chem 1991;266:6188-6194.
28. Stauble B, Boscoboinik D, Tasinato A, et al: Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and α-tocopherol in vascular smooth muscle cells. Eur J Biochem 1994;226:393-402.
29. Packer L, Suzuki YJ: Vitamin E and alphalipoate: Role in antioxidant recycling and activation of the NF-kB transcription factor. Mol Aspects Med 1993;14:229-239.
30. Okazaki T, Bell RM, Hannun YA: Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 1989;264:19076-19080.
31. Mansat-de Mas V, Bezombes C, Quillet MA, et al: Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation, and apoptosis induced by daunorubicin. Mol Pharmacol 1999;56:867-874.
32. Maziere C, Maziere C, Conte MA, et al: UVA radiation stimulates ceramide production: Relationship to oxidative stress and potential role in ERK, JNK and p38 activation. Biochem Bophys Res Commun 2001;281:289-294.
33. Takeda Y, Tashima M, Takahashi A, et al: Ceramide generation in nitric oxide induced apoptosis. Activation of magnesium dependent neutral sphingomyelinase via capsase-3. J Biol Chem 1999;274:10654-10660.
34. Hernandez O, Disher DJ, Bishopric NH, et al: Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res 2000;86:198-204.
35. Park KC, Kim DS, Kim SY, et al: Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cell Signal 2002;14:779-785.
36. Busca R, Ballotti R: Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigm Cell Res 2000;13:60-69.
37. Xu W, Gong L, Haddad MM, Bischof O, Campisi J, Yeh ET, Medrano EE: Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp Cell Res 2000;255:135-143.
38. Liu B, Andrieu-Abadie N, Levade T, et al: Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor a induced cell death. J Biol Chem 1998;273:11313-11320.
39. Singh I, Pahan K, Khan M, et al: Cytokine mediated induction of ceramide production is redox sensitive. Implications to proinflammatory cytokine mediated apoptosis in demyelinating diseases. J Biol Chem 1998;273:20354-20362.
40. Levin LA, Dutkiewicz R, Albert DM: Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res 2000;70:563-569.
41. Gouaze V, Mirault ME, Carpentier S, et al: Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin treated human breast carcinoma cells. Mol Pharmacol 2001;60:488-496.
42. Fernandez AD, Martin SF, Barroso MP, et al: Coenzyme Q protects cells against serum withdrawal induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal 2000;2:263-275.
43. Huang A, Vita JA, Venema RC, et al: Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000;275:17399-17406.
44. Everett SA, Patel KB, Michael RL, et al: Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med 2002;32:203-211.
45. Wood JM, Schallreuter-Wood KU, Lindsey NJ, et al: A specific tetrahydrobiopterin binding domain on tyrosinase controls melanogenesis. Biochem Biophys Res Commun 1995;206:480-485.
46. Schallreuter KU, Wood JM, Ziegler I: Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994;1226:181-192.
47. Wever RMF, Dam TV, Herman JM, et al: Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997;237:340-344.
48. Bertolotto C, Bille K, Ortonne JP, et al: Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: Implication of the microphthalmia gene product. J Cell Biol 1996;134:747-755.
49. Bertolotto C, Busca R, Abbe P, et al: Different cis-acting elements are involved in the regulation of TRP-1 and TRP-2 promotor activities by cyclic AMP: Pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. Mol Cell Biol 1998;18:694-702.
50. Comb M, Birnberg NC, Seasholtz A, et al: A cyclic AMP and phorbol ester inducible DNA element. Nature 1986;323:353-356.
51. Ao Y, Park HY, et al: Activation of cAMP-dependent protein kinase is required for optimal α-melanocyte-stimulating hormone-induced pigmentation. Exp Cell Res 1998;244:117-124.
52. Medrano EE, Haddad MH, Xu W, et al: Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16INK4 and p27KIP1 to CDKs, loss of E2F-binding activity and premature senescence of human melanocytes. Exp Cell Res 1999;253:561-572.
53. Gesquiere L, Loreau N, Blache D: Role of the cyclic AMP dependent pathway in free radical induced cholesterol accumulation in vascular smooth muscle cells. Free Radic Biol Med 2000;29:181-190.
54. Hu DN, et al: A functional study on prostanoid receptors involved in cultured human iridial melanocyte stimulation. Exp Eye Res 2001;73:93-100.
55. Baldwin AS: The NF-kB and the IkB proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649-681.
56. Kim YS, Ahn KS, Moon KY, et al: Downregulation of NF-kB activation in human keratinocytes by melanogenic inhibitors. J Dermatol Sci 2003;31:193-201.
57. Meyer M, Pahl HL, Baeverle PA: Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. Chem Biol Interact 1994;91:91-100.
58. Packer L, Saliou C, Kitazawa M, et al: Antioxidants modulate acute solar ultraviolet radiation induced NF-kappa B activation in a human keratinocyte cell line. Free Radic Biol Med 1999;26:174-183.
59. Flohe L, Flohe RB, Saliou C, et al: Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997;22:1115-1126.
60. Schallreuter KU, Wood JM: Thioredoxin reductase - its role in epidermal redox status. J Photochem Photobiol B 2001;64:179-184.
61. Richard MJ, et al: Induction of thioredoxin by ultraviolet A radiation prevents oxidative mediated cell death in human skin fibroblasts. Free Radic Biol Med 2001;31:585-598.
62. Yammamoto M, Sato N, Tajima H, et al: Induction of human thioredoxin in cultured human retinal pigment epithelial cells through cyclic AMP dependent pathway; involvement in the cytoprotective activity of prostaglandin E1. Exp Eye Res 1997;65:645-652.
63. Wood JM, Schallreuter KU: Reduced thioredoxin inhibits melanin biosynthesis: Evidence for the formation of a stable Bis-cysteinate complex with tyrosinase. Inorg Chim Acta 1988;151:7.
64. Schenk H, Klein M, Erdbrugger W, et al: Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci USA 1994;91:1672-1676.
65. Petrescu SM, Nichita NB, Petrescu AJ, et al: Tyrosinase folding and copper loading in vivo: A crucial role for calnexin and a-glucosidase II. Biochem Biophys Res Commun 1999;261:720-725.
66. Rao JM, Tiwari AK, Kumar US, et al: Novel 3-O-Acyl Mesquitol analogues as free radical scavengers and enzyme inhibitors: Synthesis, biological evaluation and structure-activity relationship. Bioorg Med Chem Lett 2003;13:2777-2780.
67. Yoshikawa M, Morikawa T, Matsuda H, et al: Absolute stereostructure of potent α-glucosidase inhibitor, salacinol, with unique thiosugar sulfonium sulfate inner salt structure from Salacia reticulata. Bioorg Med Chem 2002;10:1547-1554.
68. Mehta G, Senair SR: Polycyclitols: Synthesis of novel carrbasugar and conduritol analogues as potential glycosidase inhibitors. Tetrahedron Lett 1987;42:1987-1990.
69. Ohguchi K, Tanaka T, Kido T, et al: Effects of hydroxystilbene derivatives on tyrosinase activity. Biochem Biophys Res Commun 2003;307:861-863.
70. Kim Y, Shin NH, Ryu SY, et al: Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase. Biochem Biophys Res Commun 1998;243:801-803.
71. Joshi M, Strandhoy J, White WL: Nitric oxide synthase activity is up-regulated in melanoma cell lines: A potential mechanism for metastases formation. Melanoma Res 1996;6:121-126.
72. Baudouin JE, Tachon P: Constitutive nitric oxide synthase is present in normal human keratinocytes. J Invest Dermatol 1996;106:428-431.
73. Palumbo A, Poli A, Cosmo AD, et al: N-methyl-D-aspartate receptor stimulation activates tyrosinase and promotes melanin synthesis in the ink gland of the cuttlefish Sepia officinalis through the nitric oxice/cGMP signal transduction pathway. J Biol Chem 2000;275:16885-16890.
74. Palumbo A, Cosmo AD, Gesualdo I, et al: A calcium dependent nitric oxide synthase and NMDA R1 glutamate receptor in the ink gland of Sepia officinalis: A hint to a regulatory role of nitric oxide in melanogenesis? Biochem Biophys Res Commun 1997;235:429-432.
75. El-Husseini AE, et al: Nitric oxide regulates cyclic GMP-dependent protein kinase phosphorylation in rat brain. J Neurochem 1998;71:676-683.
76. Park CS, Pardhasaradhi K, Gianotti C, et al: Human retina expresses both constitutive and inducible isoforms of nitric oxide synthase mRNA. Biochem Biophys Res Commun 1994;205:85-91.
77. Traystman RJ, Kirsch JR, Koehler RC: Oxygen free radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-1195.
78. Goldstein IM, Ostwald P, Roth S: Nitric oxide: A review of its role in retinal function and disease. Vision Res 1996;36:2979-2994.
79. Romero-Graillet C, et al: Ultraviolet B radiation acts through the nitric oxide and cGMP signal transduction pathway to stimulate melanogenesis in human melanocytes. J Biol Chem 1996;271:28052-28056.
80. Romero-Graillet C, et al: Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. J Clin Invest 1997;635-642.
81. Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and its redox activated forms. Science 1992;258:1898-1902.
82. Ujihara H, Akaike A, Tamura Y, et al: Blockade of retinal NMDA receptors by sodium nitroprusside is probably due to nitric oxide formation. Jap J Pharmacol 1993;61:375-377.
83. Prota G, Vincensi MR, Napolitano A, et al: Latanoprost stimulates eumelanogenesis in Iridial melanocytes of cynomolgus monkeys. Pigment Cell Res 2000;13:147-150.
84. Vincensi MR, et al: Pheomelanin versus eumelanin as a chemical indicator of ultraviolet sensitivity in fair skinned subjects at high risk for melanoma: A pilot study. Melanoma Res 1998;8:53-58.
85. Land EJ, Ramsden CA, Riley PA: Pulse radiolysis studies of ortho-quinone chemistry relevant to melanogenesis. J Photochem Photobiol 2001;64:123-135.
86. Cooksey CJ, et al: Tyrosine mediated cytotoxicity of 4-substituted phenols: Use of QSAR to forecast reactivities of thiols towards the derived ortho-quinones. Quant Struct Act Relat 1996;15:498-503.
87. Solano F, Jara JR, Aroca P, et al: The role of sulfhydryl compounds in mammalian melanogenesis: The effect of cysteine and glutathione upon tyrosinase and the intermediates of the pathway. Biochim Biophys Acta 1988;967:296-303.
88. Thompson A, Land EJ, Chedekel MR, et al: A pulse radiolysis investigation of the oxidation of the melanin precursors 3,4-dihydroxyphenylalanine (dopa) and the cysteinyldopas. Biochim Biophys Acta 1985;843:49-57.
89. Flohe L, et al: Redox regulation of NF-Kappa B activation. Free Radic Biol Med 1997;22:1115-1126.
90. Yonemoto K, Gellin GA, et al: Reduction in eumelanin by the activation of glutathione reductase and gamma-glutamyl transpeptidase after exposure to a depigmenting chemical. Biochem Pharmacol 1983;32:1379-1382.
91. Ursini F, Majorino M, Flohe RB, et al: Diversity of glutathione peroxidases. Methods Enzymol 1995;252:38-53.
92. Ozeki H, et al: Chemical characterization of pheomelanogenesis starting from dihydroxyphenylalanine or tyrosine and cysteine. Effects of tyrosinase and cysteine concentrations and reaction time. Biochim Biophys Acta 1997;1336:539-548.
93. Thody A, et al: Tyrosinase and the regulation of coat color changes in C3H-HeAvy mice. Pigment Cell Res 1992;5(pt 2):335-339.
94. Thody AJ, Ancans J: Activation of melanogenesis by vacuolar type H+ ATPase inhibitors in amelanotic, tyrosinase positive human and mouse melanoma cells. FEBS Lett 2000;478:57-60.
95. Fuller BB, Spaulding DT, Smith DR: Regulation of the catalytic activity of preexisting tyrosinase in black and Caucasian human melanocyte cell cultures. Exp Cell Res 2001;262:197-208.
96. Ito S, et al: Effects of genic substitution at the agouti, brown, albino, dilute and pink eyed dilution loci on the proliferation and differentiation of mouse epidermal melanocytes in serum free culture. Eur J Cell Biol 1998;75:184-191.
97. Rinchik E, Bultman SJ, Horsthemke B, et al: A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 1993;361:72-76.
98. Landrum JT, Bone RA, Kilburn MD: The macular pigment: A possible role in protection from age related macular degeneration. Adv Pharmacol 1997;38:537-556.
99. Schallreuter KU, et al: Pteridines in the control of pigmentation. J Invest Dermatol 1997;109:31-35.
100. Hammond BR, Wooten BR, Snodderly DM: Preservation of visual sensitivity of older subjects: Association with macular pigment density. Invest Ophthalmol Vis Sci 1998;39:397-406.
101. Zen K, Biwersi J, Periasamy N, et al: Second messengers regulate endosomal acidification in Swiss 3T3 fibroblasts. J Cell Biol 1992;119:99-110.
102. Wolff SP, et al: Prooxidant activation of ocular reductants I. Copper and riboflavin stimulate ascorbate oxidation causing lens epithelial cytotoxicity in vitro. Exp Eye Res 1987;45:777-789.
103. Sasaki H, et al: A protective role for glutathione-dependent reduction of dehydroascorbic acid in lens epithelium. Invest Ophthalmol Vis Sci 1995;36:1804-1817.
104. Slepneva IA, Khramtsov VV, Sergeeva SV: Reversible inhibition of NADPH-cytochrome P450 reductase by alpha lipoic acid. Biochem Biophys Res Commun 1995;214:1246-1253.
105. Moini H, Tirosh O, Park YC, et al: R-alphalipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys 2002;397:384-391.
106. Aguilar JS, Metodiewa D, Jaiswal AK, et al: Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med 1999;26:107-116.
107. Cao G, et al: Antioxidant and prooxidant behavior of flavonoids: Structure activity relationships. Free Radic Biol Med 1997;22:749-760.
108. Nohl H, Gille L, Kozlov AV: Antioxidant derived prooxidant formation from ubiquinol. Free Radic Biol Med 1998;25:666-675.
109. Beatty S, et al: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
110. Cai J, Nelson KC, Wu M, et al: Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205-221.
111. Nelson KC, Carlson J, Newman ML, et al: Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthal Vis Res 1999;40:1927-1935.
112. Brown DA: Skin pigmentation enhancers. J Photochem Photobiol B2001;63:148-161.